Related Experiment Video
Updated: Jul 11, 2025
10:13
Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
Published on: February 14, 2014
13.7K
Metformin, age-related cognitive decline, and brain pathology
Ajay Sood1, Ana Werneck Capuano1, Robert Smith Wilson1
1Rush Alzheimer's Disease Center, Chicago, IL, USA.
Neurobiology of Aging
|November 6, 2023
Summary
Metformin use was associated with slower cognitive decline, particularly in episodic and semantic memory, over an 8-year period. However, it did not significantly impact Alzheimer's disease pathology or overall infarcts in brain autopsy studies.
Area of Science:
- Neurology
- Gerontology
- Pharmacology
Background:
- Cognitive decline and neurodegenerative diseases pose significant public health challenges.
- Metformin is a widely prescribed medication for type 2 diabetes.
- Understanding the long-term effects of metformin on cognitive function and brain health is crucial.
Purpose of the Study:
- To investigate the association between metformin use and cognitive changes over time.
- To examine the relationship between metformin and specific brain pathologies, including Alzheimer's disease markers and infarcts.
- To evaluate the impact of metformin on cognitive domains such as global cognition, episodic memory, and semantic memory.
Main Methods:
- Longitudinal study design with a mean follow-up of 8 years.
- Linear mixed-effects models adjusted for age, sex, and education to assess cognitive decline.
- Analysis of autopsy data to evaluate Alzheimer's disease pathology and infarcts.
- Sensitivity analyses including all diabetes medication use.
Main Results:
- Metformin users exhibited a significantly slower decline in global cognitive scores compared to non-users (p=0.027).
- Specific cognitive domains, including episodic and semantic memory, showed a slower rate of decline in metformin users.
- No significant differences in overall Alzheimer's disease pathology or infarcts were observed between metformin users and non-users in autopsy samples.
- Metformin users had higher odds of subcortical infarcts but lower odds of atherosclerosis and arteriosclerosis.
Conclusions:
- Metformin use may be associated with a protective effect against cognitive decline, particularly in memory-related functions.
- The observed cognitive benefits of metformin do not appear to be directly linked to reduced Alzheimer's disease pathology or overall infarct burden.
- Further research is warranted to elucidate the mechanisms underlying metformin's potential neuroprotective effects and its specific impact on cerebrovascular health.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
01:26Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
01:30Cognitive Development During Adulthood
122
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
122
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
130
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
130
01:26Aging
59
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
59
01:22Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197